Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

High Cost of Rheumatoid Arthritis Medications Burdens Patients in Saudi Arabia

Lina El Kibbi  |  Issue: March 2017  |  March 20, 2017

In addition, we hope to find charities that can fund patients who are not insured or have problems with their insurance. Let us live 24 hours with these patients to feel their daily agony.


Lina El KibbiLina El Kibbi is a rheumatology consultant, adjunct assistant professor at Alfaisal University and director of medical academic affairs for the Specialized Medical Center Hospital (see image above) in Riyadh, Saudi Arabia.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabburdenCertolizumab PegolcostsdrugetanerceptexpenseGolimumabinfliximabMedicationPatientsRheumatoid arthritisrheumatologySaudia Arabia

Related Articles

    Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies

    October 14, 2015

    Receipt of an unsolicited communication that a sweepstakes award has been won may con some people (especially, but not limited to, those underprivileged or undereducated as to legalities), but can’t fool all of the people all of the time. The names of the organizations and products involved are often marketing tool inventions, which imply special…

    The American College of Rheumatology (ACR) can Help Combat Insurance Frustrations

    April 6, 2012

    When it comes to dealing with insurance companies, the rules seem to change frequently and always in an arbitrary and capricious way. The ACR is trying its best to protect rheumatologists, but we need your help!

    Stripping Americans of Health Insurance Could Be Deadly

    June 29, 2017

    (Reuters Health)—Health insurance saves lives—that’s the conclusion of a report released on Monday, just in time to weigh into the debate among Senate Republicans considering a bill that could strip millions of Americans of coverage. “Overwhelming scientific evidence shows that lack of insurance is sometimes deadly,” co-author Dr. David Himmelstein, a professor at the City…

    Institute for Clinical Economic Review Final Report on RA Treatments

    May 4, 2017

    On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences